Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here you go:
http://www.morningstar.com/earnings/36157108-merck-kgaa-adr-q4-2011.aspx
Annalisa Jenkins - Global Head of Drug Development & Medical: Thank you. Thanks for question, Richard. What I'd like to do is address the two different parts of your question together and just note that this was actually second of two planned interims which were pre-specified in the original statistical analysis plan as approved by the agencies and this pre-specified interim as is often the case in these very long studies, was primarily put in place when we had accrued 75% of the pre-planned end points to ensure that in the spirit of protecting patients, we could stop if we saw that there would be no expected ability to show benefits or to reach the primary endpoints or if there was overwhelming evidence at this stage in the study of an efficacy benefit. So, how I would advise you to interpret our announcement; the study will continue as planned to its completion, and if you remember this is a study that is event driven. We will go to accrual of 100% of events and we've already stated today that we expect that to be – that that events be reached towards the end of this year and then subsequently post data analysis we'll see the data early next year. So, hopefully that addresses your question in that this was an interim, it was pre-specified, it allowed us to stop the overwhelming efficacy or no expectation of benefit. The committee reviewed the data, they saw no safety issues and they advised us that we should continue?
So what do you think happened here? Why would the FDA give them a severely stringent endpoint at the second interim? ---- unless of course Kirkman is just lying and their try to buy time.
Or, do you think, as with Yervoy, there is a delayed reaction w the immunotherapy?
Who knows...what I do know is that Kirkman is a moron and should just be straight for once.
You are correct. Kirkman said absolutely NO such thing
pcrutch posted what Gekkowire posted on twitter ---- and gekkowire has no clue and is guessing, just like everyone else.
No, these numbers are from GekkoWire tweet, who is guessing----because Kirkman said absolutely no such thing on the conference call.
I would love that since I am long, and recently bought below $1.30, but, me thinks you are just pumping, unless you have a specific reason for your $5 price.
Does anyone actually know what the efficacy halt endpoints were for the 2IA, instead of blatant speculation (which all started the blow-away numbers to begin with, with the stat analysis).
Why is it a big secret
I don't think it is out of the question at all that this trial succeeds at the final.
The fact of the matter is the exuberance created by these false models of statistical analysis goosed everyone's expectations of the 2IA - and got a lot of idiots involved in the stock - which probably also got a lot of generalist hedge funds involved in the name also.
I mean, really. How many drugs in Phase 3 are actually halted for efficacy at the 2IA?
Further, they still do have PX-866 which has shown some decent results - so it's not like a market-cap $250 million is crazy. Lots of crap out there trading at higher valuations.
So why do you think the bull-case was not met? (Despite the obvious = they missed the HR/pv)
Let me guess.....Rodman, with Roth in the mix as well?
I have been away, but, did KERX seriously go up $1.25 today because of an article from a notorious SeekingAlpha pumping hack?
Jeremy Richards should be banned from Seeking Alpha. This is the same clown that wrote Roche (from what i can remember) was "definitely" going to buy KERX (and he even put a date on it)(which has passed many times over).
IMO, he probably owns KERX at $9
I disagree.
I don't think they're gonna be raising any more money this year.
Four drugs:
1. AP-26113 - wholly owned
2. Pontanib - wholly owned
3. Ridaforolimus - partnered (Merck)
4. AP1903 - outlicensed (Bellicum)
There's your (4)
Why do you think they're going to issue another 10 million later this year?
Is everyone here expecting a massive earnings beat tomorrow?? LOL!! Because, we all know, the Street all is "here" because this is an "earnings story" (lol)
I wonder if they ever got any offers for the entire company (by a pharma who could have actually done a much better job selling/marketing) several billion dollars in market cap higher.
I hope there's not a buyout because I dn't own enough stock right now if there is one :)
Try not to forget the "sell on the news" effect.
I hope '113 can keep a bid under the stock at that point. That will be the real driver to higher prices (higher market cap).
Wonderful. More wars to screw up the global ecomony and our recovery.
IMO, we need to stay out of other peoples business.
Are you following the abraxane + gemcitabine trials at all?
I'm curious to see how you feel about this combination versus the 302 drug trial.
Are you saying they shouldn't have recommended approval?
I have no position either way.
I see them approving the drug. I don't know how successful it will be financially, however.
OOOH OOOH... I GOT THIS ONE!
How about..... the IBB was down 30 points or around 2.5%.
Personally, I hope this "comes in" so I can buy the crap out of it.
Good. I'll be a buyer again.
overlay the IBB with ARIA. They almost track identically. There is a fairly painful pullback in progress right now, but, not anything to cry about (yet). The internals of the NASDAQ look like CRAPOLA.
I woud have to say that I should have sold every single one of my biotech holdings last week when there was nothing but congratulatory backslapping from everyone with a twitter account who owned a biotech stock thinking they were geniuses. Stupid me. Only sold some.
Either way, to answer your question. A negative result from Ridaforolimus? I dnt know...a point and a half downside? 10%? Who here has even mentioned Ridaforolimus in the past six months?
There are some really crappy internals to this market. Basically, the NASDAQ close down 3 points today, but biotech got croaked - .BTK down 30 - that's nasty. The only reason the NASDAQ is looking good (superficially) is because of AAPL and a handful of other stocks. Everything else looks like its in correction, garbage mode.
What you say Andy?
The easy money has been made here IMO. Doesn't mean it's not going much higher on any type of '113 positive news. However, the whole sector is pulling back - it's natural. This is still one of the few very good biotech ideas out there.
But, when, at $7.50, you had about 40% institutional ownership, at $14.50, institutional sponsorship is now closing in on probably 80% - it's not like there's many major buyers out there who haven't heard the story yet.
Yes. Very ugly.
It's only gone up about 50% since the middle of December. LOL
Didnt we already go through this several months ago? LOL.
Berger's sale was a tax liability due to vesting. Irrelevant IMO. Executives do this every single month at some companies.
Actually, typo-
"REGN" should have read "GILD" - which has an even bigger weighting at $40 billion market cap.
My bad. (was looking at the wrong screen)
..besides the fact that a lot of the moves today are driven by op-ex gamma moves etc
ARIA (and many biotechs in general), many days *(unless ARIA has specific news driven event) trade directly with the ETF biotech index's (more or less) - - ESPECIALLY on low volume days (like today). My entire screen is red. IBB and .BTK-P are straight down, and its dragging sector with it. IMO, and from what I can tell directly from my screen, daily, is that when a large market cap stock is affected either up big or down big (on news, or whatever event is driving it), it tends to drag the entire sector red, or green, with it. --today's driver seems to be REGN which has a $10 billion market cap and is prob weighted more heavily in these indexes.
It's an ETF/algorithm world now----we just all happen to live in it.
OK, so maybe Milton.
He deserves it. That'll buy him a nice pad in Weston or Concord.
Be interesting to see if Berger ever starts selling.